State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, P.R. China; National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen, P.R. China.
State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong, P.R. China; Joint Institute of Virology (Shantou University and The University of Hong Kong), Guangdong-Hongkong Joint Laboratory of Emerging Infectious Diseases, Shantou University, Shantou, P.R. China.
Cell Rep. 2022 Mar 22;38(12):110558. doi: 10.1016/j.celrep.2022.110558. Epub 2022 Mar 7.
Mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD) may alter viral host tropism and affect the activities of neutralizing antibodies. Here, we investigated 153 RBD mutants and 11 globally circulating variants of concern (VOCs) and variants of interest (VOIs) (including Omicron) for their antigenic changes and cross-species tropism in cells expressing 18 ACE2 orthologs. Several RBD mutations strengthened viral infectivity in cells expressing ACE2 orthologs of non-human animals, particularly those less susceptible to the ancestral strain. The mutations surrounding amino acids (aas) 439-448 and aa 484 are more likely to cause neutralization resistance. Strikingly, enhanced cross-species infection potential in the mouse and ferret, instead of the neutralization-escape scores of the mutations, account for the positive correlation with the cumulative prevalence of mutations in humans. These findings present insights for potential drivers of circulating SARS-CoV-2 variants and provide informative parameters for tracking and forecasting spreading mutations.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)刺突受体结合域(RBD)的突变可能改变病毒的宿主嗜性,并影响中和抗体的活性。在这里,我们研究了 153 个 RBD 突变体和 11 个全球流行的关切变异株(VOCs)和感兴趣变异株(VOIs)(包括奥密克戎),以评估它们在表达 18 种 ACE2 同源物的细胞中的抗原变化和跨物种嗜性。一些 RBD 突变增强了表达非人类动物 ACE2 同源物的细胞中的病毒感染力,特别是那些对原始毒株敏感性较低的细胞。围绕氨基酸(aa)439-448 和 aa484 的突变更有可能导致中和耐药性。引人注目的是,在小鼠和雪貂中增强的跨物种感染潜力,而不是突变的中和逃逸评分,与突变在人群中累积流行率呈正相关。这些发现为循环 SARS-CoV-2 变异株的潜在驱动因素提供了见解,并为跟踪和预测传播突变提供了有价值的参数。